Liquid Biopsy of Durvalmab for locally advanced NSCLC

Liquid Biopsy of Durvalmab for locally advanced NSCLC - Liquid Biopsy of Durvalmab for locally advanced NSCLC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034952

Enrollment

Registered

2018-11-20

Start date

2018-09-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with chemoradiotherapy followed by durvalmab for advanced NSCLC

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To explore expressions of immune-related proteins before- and after chemoradiotherapy follow by durvalmab for locally advanced non-small cell lung cancer	—

Countries

Japan

Contacts

Public ContactShoko Kawai

Tokyo Metropolitan Komagome Hospital Department of Thoracic Oncology

y-okuma@cick.jp03-3823-2101

Outcome results